Evicel - summary of medicine characteristics

1. NAME OF THE MEDICINAL PRODUCT

EVICEL solutions for sealant

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

The active ingredients are as follows:

Total quantity of protein is 80 – 120 mg/ml

For the full list of excipients see section 6.1.

3. PHARMACEUTICAL FORM

Solutions for sealant.

Clear or slightly opalescent solutions.

4. CLINICAL PARTICULARS4.1 Therapeutic indications

EVICEL is indicated in adults as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis (see section 5.1).

EVICEL is also indicated in adults as suture support for haemostasis in vascular surgery and for suture line sealing in dura mater closure.

4.2 Posology and method of administration

The use of EVICEL is restricted to experienced surgeons who have been trained in the use of EVICEL.

Posology

The volume of EVICEL to be applied and the frequency of application should always be oriented towards the underlying clinical needs of the patient.

The dose to be applied is governed by variables including, but not limited to, the type of surgical intervention, the size of the area and the mode of intended application and the number of applications. Application of the product must be individualised by the treating physician. In controlled clinical trials in vascular surgery, the individual dosage used was up to 4 ml; for suture line sealing in dura mater closure, doses of up to 8 ml were used, whereas in retroperitoneal or intra-abdominal surgery the individual dosage used was up to 10 ml. However, for some procedures (e.g., liver traumata) larger volumes may be required.

The initial volume of the product to be applied at a chosen anatomic site or target surface area should be sufficient to entirely cover the intended application area. The application can be repeated, if necessary.

Method of administration

Evicel is for epilesional use.

For instructions on preparation of the medicinal product before administration, see section 6.6. The product should only be administered according to the instructions and with the devices recommended for this product (see section 6.6).

Prior to applying EVICEL the surface area of the wound needs to be dried by standard techniques (e.g. intermittent application of compresses, swabs, use of suction devices).

To avoid the risk of potentially life-threatening air or gas embolism EVICEL should be sprayed using pressurised CO2 gas only. For spray application see sections 4.4 and 6.6 for specific recommendations on the required pressure and distance from tissue per surgical procedure and length of applicator tip.

4.3 Contraindications

EVICEL must not be applied intravascularly.

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Spray application of EVICEL should not be used in endoscopic procedures. For laparoscopy, see section 4.4.

EVICEL must not be used for sealing the suture line in dura mater if there are gaps of greater than 2 mm after suturing.

EVICEL must not be used as a glue for the fixation of dural patches.

EVICEL must not be used as a sealant when the dura mater cannot be sutured.

4.4 Special warnings and precautions for use

EVICEL is for epilesional use only. It must not be applied intravascularly.

Life-threatening thromboembolic complications may occur if the product is unintentionally applied intravascularly.

Life-threatening air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer EVICEL. This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface.

EVICEL spray application should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy. Spray distance from tissue and CO2 pressure should be within the ranges recommended by the manufacturer (see table in section 6.6 for pressure and distance).

When spraying EVICEL, changes in blood pressure, pulse, oxygen saturation, and end tidal CO2 should be monitored because of the possibility of occurrence of a gas embolism.

When using accessory tips with this product, the instructions for use of the tips should be followed.

Before administration of EVICEL, care is to be taken that parts of the body outside the desired application area are sufficiently protected (covered) to prevent tissue adhesion at undesired sites.

EVICEL should be applied as a thin layer. Excessive clot thickness may negatively interfere with the product’s efficacy and the wound healing process

Adequate data are not available to support the use of this product in tissue gluing, application through a flexible endoscope for treatment of bleeding, or in gastrointestinal anastomoses.

As with any protein product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur, the administration should be discontinued immediately.

In case of shock, standard medical treatment for shock should be implemented.

The concomitant use of EVICEL for dural suture line sealing with implants from synthetic materials or dural patches has not been evaluated in clinical studies.

The use of EVICEL in patients undergoing radiotherapy within 7 days after surgery has not been evaluated. It is not known whether radiation therapy could affect the efficacy of fibrin sealant when used for suture line sealing in dura mater closure.

Complete haemostasis should be achieved before application of EVICEL to seal the dural suture line.

The use of EVICEL as a sealant in transphenoidal and otoneurosurgical procedures has not been studied.

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection, and the inclusion of effective manufacturing steps for the inactivation/re­moval of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infectious agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, hepatitis C virus, and hepatitis B virus, and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g., haemolytic anaemia).

It is strongly recommended that every time EVICEL is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g., antiseptic solutions). Such substances should be removed to the greatest possible extent before applying the product.

4.6 Fertility, pregnancy and lactation

The safety of fibrin sealants/haemos­tatics for use in human pregnancy or during breast-feeding has not been established in controlled clinical trials. Experimental animal studies are insufficient to assess the safety with respect to reproduction, development of the embryo or foetus, the course of gestation, and peri- and post-natal development. Therefore, the product should be administered to pregnant and breast-feeding women only if clearly needed.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the application site, bronchospasm, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) may occur in rare cases in patients treated with fibrin sealants/haemos­tatics. In isolated cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to constituents of the product.

Antibodies against components of fibrin sealant/haemostatic products may occur rarely.

Inadvertent intravascular injection could lead to thromboembolic event and disseminated intravascular coagulation (DIC), and there is also a risk of anaphylactic reaction (see section 4.4).

Life-threatening air or gas embolism has occurred with the use of spray devices employing pressure regulator to administer EVICEL. This event appears to be related to the use of the spray device at higher than recommended pressures and/or in close proximity to the tissue surface.

For safety with respect to transmissible agents, see section 4.4.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

Description of selected adverse reactions

Adverse reaction rates in retroperitoneal or intra -abdominal surgery studies

Among 135 patients undergoing retroperitoneal and intra-abdominal surgery (67 patients treated with EVICEL and 68 controls), no adverse events were considered to be causally related to the study treatment according to the investigator assessments. However, 3 serious adverse events (SAE) (one abdominal abscess in the EVICEL group and one abdominal and one pelvic abscess in the control group) were considered by the Sponsor to be possibly related to study treatment.

In a study in a paediatric population involving 40 patients (20 patients treated with EVICEL and 20 controls), two adverse events (pyrexia and coagulopathy) were considered possibly related to EVICEL by the investigator.

Adverse reactions – vascular surgery

In a controlled study involving 147 patients undergoing vascular grafting procedures (75 treated with EVICEL and 72 controls), a total of 16 subjects were reported to have had a graft thrombosis/oc­clusion adverse event during the study period. The events were evenly distributed across treatment arms, with 8 each in the EVICEL and the control groups.

A non-interventional post-authorisation safety study was conducted which involved 300 patients undergoing vascular surgery during which EVICEL was used. Safety monitoring focused on the specific adverse reactions of graft patency, thrombotic events, and bleeding events. No adverse reactions were reported during the study.

Adverse reactions – neurosurgery

In a controlled study involving 139 patients undergoing elective neurosurgical procedures (89 treated with EVICEL and 50 controls), a total of 7 subjects treated with EVICEL experienced nine AEs that were considered to be possibly related to the study product. These included intracranial hypotension (CSF leakage), CSF rhinorrhea, meningitis, headache, hydrocephalus, subdural hygroma, and haematoma.

The incidence of CSF leakage and the incidence of Surgical Site Infections were monitored as safety endpoints in the study. At 30 days post-operatively the incidence of SSIs was similar between the two treatment groups. Post-operative CSF leakage occurred within 30 days from treatment in 4/89 (4.5%) subjects treated with EVICEL (two cases of CSF leakage with impaired wound healing and two cases of rhinorrhoea) and in 1/50 (2.0%) subjects treated with additional sutures.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in

4.9 Overdose

No case of overdose has been reported.

5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties

Pharmacotherapeutic group: local haemostatics, combinations, ATC code: B02BC30

Mechanism of action

The fibrin adhesion system initiates the last phase of physiological blood coagulation. Conversion of fibrinogen into fibrin occurs by the splitting of fibrinogen into fibrin monomers and fibrinopeptides. The fibrin monomers aggregate and form a fibrin clot. Factor XIIIa, which is activated from Factor XIII by thrombin, crosslinks fibrin. Calcium ions are required for both, the conversion of fibrinogen and the crosslinking of fibrin. As wound healing progresses, increased fibrinolytic activity is induced by plasmin and decomposition of fibrin to fibrin degradation products is initiated.

Clinical efficacy and safety

Clinical studies demonstrating haemostasis and suture support were conducted in a total of 147 patients (75 with EVICEL, 72 with control) undergoing vascular surgery with PTFE grafts and in a total of 135 patients (66 with EVICEL, 69 with control) undergoing retroperitoneal and intra-abdominal surgery.

The efficacy of EVICEL for suture line sealing in dura mater closure was demonstrated in 139 patients (89 treated with EVICEL and 50 controls) undergoing craniotomy/cra­niectomy procedures.

Paediatric population

Limited paediatric data are available to support efficacy and safety of EVICEL in this population. Of 135 patients undergoing retroperitoneal and intra-abdominal surgery who were included in the controlled study of EVICEL, 4 paediatric patients were treated with EVICEL. Of these, 2 were children aged 2 and 5 years and 2 were adolescents of 16 years. In addition, a paediatric controlled clinical study evaluating the safety and effectiveness of EVICEL as an adjunct to haemostasis in soft tissue or parenchymal organ bleeding was conducted in 40 patients (20 treated with EVICEL and 20 controls). The patients age range was from 11 months to 17 years. Data from this study were consistent with results from the previous study in retroperitoneal and intra-abdominal surgery where non-inferior haemostatic efficacy of EVICEL was demonstrated.

5.2 Pharmacokinetic properties

EVICEL is intended for epilesional use only. Intravascular administration is contraindicated. As a consequence, intravascular pharmacokinetic studies were not performed in man.

Studies have been conducted in rabbits to evaluate the absorption and elimination of thrombin when applied to the cut surface of the liver resulting from partial hepatectomy. Using 125I-thrombin it was shown that a slow absorption of biologically inactive peptides resulting from the breakdown of thrombin occurred, reaching a Cmax in the plasma after 6–8 hours. At the Cmax, the plasma concentration represented only 1–2% of the applied dose.

Fibrin sealants/haemos­tatics are metabolised in the same way as endogenous fibrin, by fibrinolysis and phagocytosis.

5.3 Preclinical safety data

Studies performed in bacteria to determine mutagenicity were negative for thrombin alone, Biological Active Component (containing fibrinogen, citrate, glycine, tranexamic acid, and arginine hydrochloride), TnBP alone, and Triton X-100 alone at all concentrations tested. All concentrations of the combination of TnBP and Triton X-100 also tested negative in assays performed to determine mammalian cell mutagenicity, chromosomal aberrations and micronuclei induction.

After local application, absorption of thrombin into the plasma is slow and consists principally of thrombin degradation products which are eliminated.

No toxicological effects due to the solvent detergent reagents (TnBP and Triton X-100) used in the virus inactivation procedure are expected since the residual levels are less than 5 ^g/ml.

Neurotoxicity studies performed with EVICEL confirmed that subdural administration in the rabbit was not associated with any evidence of neurotoxicity. Neurobehavioral observations for 14±1 days showed no abnormal findings. No major macroscopic signs of local intolerance and no treatment-related macroscopic findings were observed. Analysis of cerebrospinal fluid did not reveal major signs of inflammation.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Human fibrinogen vial

Arginine hydrochloride

Glycine

Sodium chloride

Sodium citrate

Calcium chloride

Water for injections

Human thrombin vial

Calcium chloride

Human albumin

Mannitol

Sodium acetate

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

2 years.

Within the 2 years shelf life, after thawing, unopened vials can be stored at 2°C – 8°C and protected from light, for up to 30 days. The vials can be stored at room temperature for up to 24 hours. By the end ofthis period the product has to be used or discarded.

6.4 Special precautions for storage

Store in a freezer at or below –18°C. Do not refreeze.

Keep the vials in the outer carton in order to protect from light.

The vials must be stored in an upright position.

For storage conditions after thawing of the medicinal product, see section 6.3. The new expiry date at 2°C-8°C should be noted on the carton but should not exceed the expiry date printed by the manufacturer on the carton and label. At the end of this period the product has to be used or discarded.

Once drawn up into the application device, the product must be used immediately.

6.5 Nature and contents of container

EVICEL is supplied as a package containing two separate vials (glass type I) with rubber stoppers (type I), each containing 1 ml, 2 ml, or 5 ml solution of Human Fibrinogen and Human Thrombin, respectively.

An application device and appropriate accessory tips are supplied separately.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

The instructions for use are also described in the healthcare professionals package leaflet part.

The solutions are clear or slightly opalescent. Solutions that are cloudy or have deposits should not be used.

Thawing

The vials should be thawed in one of the following ways:

2°C-8°C (refrigerator): vials thaw within 1 day, or

20°C-25°C (room temperature): vials thaw within 1 hour, or

37°C (e.g., water bath, using aseptic technique, or by warming vials in the hand): vials should be thawed within 10 minutes and must not be left at this temperature for longer than 10 minutes or until fully thawed. The temperature must not exceed 37° C.

Before use, the product must reach 20–30°C.

Device assembly

EVICEL should only be applied using the CE-marked EVICEL application device and optional use of accessory tips to the device. Leaflets giving detailed instructions for use of EVICEL in conjunction with the application device and optional accessory tips are provided with the package of the application device and of the accessory tips. The accessory tips should only be used by persons adequately trained in laparoscopic, laparoscopic-assisted, or open surgical procedures.

Draw the contents of the two vials into the application device, following the instructions for use in the device package. Both syringes should be filled with equal volumes, and should not contain air bubbles. No needles are involved in the preparation of EVICEL for administration.

Application by dripping

Keeping the tip of the applicator as close to the tissue surface as possible, but without touching the tissue during application, apply individual drops to the area to be treated. If the applicator tip becomes blocked, the catheter tip can be cut back in 0.5 cm increments.

Spray application

To avoid the risk of potentially life-threatening air or gas embolism EVICEL should be sprayed using pressurized CO2 gas only (see table below).

The pressure regulator should be used in accordance with the manufacturer’s in­struction.

Connect the short tube on the application device to the male luer-lock end of the long gas tube. Connect the female luer lock of the gas tube (with the 0.2 |im bacteriostatic filter) to a pressure regulator.

When applying EVICEL using a spray device, it has to be ensured that the pressure and the distance from the tissue are within the ranges recommended by the marketing authorisation holder of this product, as given in the following table:

The product should then be sprayed onto the surface of the tissue in short bursts (0.1–0.2 ml) to form a thin, even layer. EVICEL forms a clear film over the area of application.

When spraying EVICEL, changes in blood pressure, pulse, oxygen saturation and end tidal CO2 should be monitored because of the possibility of occurrence of gas embolism.

When using accessory tips with this product, the instructions for use of the tips should be followed.

Disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Omrix Biopharmaceuticals N.V.

Leonardo Da Vinci Laan 15

B-1831 Diegem

Belgium

Tel: + 32 2 746 30 00

Fax: + 32 2 746 30 01

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/473/001

EU/1/08/473/002

EU/1/08/473/003

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 06 October 2008

Date of latest renewal: 23 August 2018